Price$70.53+39.62 (+128.20%)
2025-08-132025-11-13
Latest news
25 items- SECSEC Form 15-12G filed by Metsera Inc.15-12G - Metsera, Inc. (0002040807) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)
- INSIDERSee Remark 1 Fmr Llc disposed of 2,233,460 shares (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERDirector Arch Venture Partners Xii, Llc returned 26,816,808 shares to the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Metsera Inc.SCHEDULE 13D/A - Metsera, Inc. (0002040807) (Subject)
- SECSEC Form SCHEDULE 13G filed by Metsera Inc.SCHEDULE 13G - Metsera, Inc. (0002040807) (Subject)
- INSIDERCHIEF LEGAL OFFICER Lang Matthew returned 12,500 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERDirector Berns Paul L returned 16,798,952 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Marso Steven returned 17,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERLarge owner Population Health Partners Gp, Llc returned 12,767,462 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERDirector Burow Kristina returned 51,414,082 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERLarge owner Validae Health, L.P. disposed of 12,767,462 shares, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERDirector Stonehouse Jon P returned 2,688 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERDirector Pinto Joshua returned 2,688 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Hubbard Brian returned 17,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDEROfficer Bernard Christopher Whitten returned 12,788,712 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Visioli Christopher returned 21,250 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- INSIDEREXECUTIVE CHAIRMAN Meanwell Clive returned 12,772,837 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- SECSEC Form S-8 POS filed by Metsera Inc.S-8 POS - Metsera, Inc. (0002040807) (Filer)
- SECMetsera Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Leadership Update8-K - Metsera, Inc. (0002040807) (Filer)
- SECSEC Form 25-NSE filed by Metsera Inc.25-NSE - Metsera, Inc. (0002040807) (Subject)
- PRPfizer Completes Acquisition of MetseraAcquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer's Internal Medicine portfolio Positions Pfizer to lead in one of the most dynamic and high-growth therapeutic areas Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. "This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resou
- SECSEC Form 10-Q filed by Metsera Inc.10-Q - Metsera, Inc. (0002040807) (Filer)
- INSIDERSee Remark 1 Fmr Llc gifted 860,722 shares (SEC Form 4)4 - Metsera, Inc. (0002040807) (Issuer)
- SECSEC Form DEFA14A filed by Metsera Inc.DEFA14A - Metsera, Inc. (0002040807) (Filer)
MTSR FAQ
6 questionsWhere does MTSR stock trade?
Metsera Inc. (MTSR) is listed on NASDAQ.What sector and industry is MTSR in?
Metsera Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Metsera Inc. go public?
Metsera Inc. (MTSR) completed its IPO in 2025.What are analysts saying about MTSR?
Metsera Inc. has had 6 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight on 2025-09-30. Recent price targets cluster around $3800.00.What companies are similar to MTSR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MTSR side-by-side with any of them on Quantisnow.How can I track MTSR on Quantisnow?
Quantisnow aggregates Metsera Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MTSR to receive live email and push alerts on every new disclosure.